首页> 外文期刊>Journal of Internal Medicine >Systems cancer medicine: Towards realization of predictive, preventive, personalized and participatory (P4) medicine
【24h】

Systems cancer medicine: Towards realization of predictive, preventive, personalized and participatory (P4) medicine

机译:系统癌症医学:实现预测,预防,个性化和参与性(P4)医学

获取原文
获取原文并翻译 | 示例
           

摘要

A grand challenge impeding optimal treatment outcomes for patients with cancer arises from the complex nature of the disease: the cellular heterogeneity, the myriad of dysfunctional molecular and genetic networks as results of genetic (somatic) and environmental perturbations. Systems biology, with its holistic approach to understanding fundamental principles in biology, and the empowering technologies in genomics, proteomics, single-cell analysis, microfluidics and computational strategies, enables a comprehensive approach to medicine, which strives to unveil the pathogenic mechanisms of diseases, identify disease biomarkers and begin thinking about new strategies for drug target discovery. The integration of multidimensional high-throughput 'omics' measurements from tumour tissues and corresponding blood specimens, together with new systems strategies for diagnostics, enables the identification of cancer biomarkers that will enable presymptomatic diagnosis, stratification of disease, assessment of disease progression, evaluation of patient response to therapy and the identification of reoccurrences. Whilst some aspects of systems medicine are being adopted in clinical oncology practice through companion molecular diagnostics for personalized therapy, the mounting influx of global quantitative data from both wellness and diseases is shaping up a transformational paradigm in medicine we termed 'predictive', 'preventive', 'personalized', and 'participatory' (P4) medicine, which requires new strategies, both scientific and organizational, to enable bringing this revolution in medicine to patients and to the healthcare system. P4 medicine will have a profound impact on society - transforming the healthcare system, turning around the ever escalating costs of healthcare, digitizing the practice of medicine and creating enormous economic opportunities for those organizations and nations that embrace this revolution.
机译:疾病的复杂性是阻碍癌症患者获得最佳治疗结果的巨大挑战:细胞异质性,遗传(体细胞)和环境扰动导致无数功能失调的分子和遗传网络。系统生物学以其整体方法来理解生物学的基本原理,以及基因组学,蛋白质组学,单细胞分析,微流体学和计算策略中的授权技术,从而为医学提供了一种综合方法,力图揭示疾病的致病机制,识别疾病生物标志物,并开始考虑药物靶标发现的新策略。来自肿瘤组织和相应血液样本的多维高通量“组学”测量结果的集成,以及用于诊断的新系统策略,使得能够识别癌症生物标志物,从而实现症状前诊断,疾病分层,疾病进展评估,评估患者对治疗的反应和复发的识别。尽管系统医学的某些方面已通过伴随分子诊断在临床肿瘤学实践中用于个性化治疗,但来自健康和疾病的全球定量数据的大量涌入正在塑造一种医学上的变革范式,我们称之为“预测性”,“预防性” ,“个性化”和“参与式”(P4)医学,这需要科学和组织上的新策略,才能使这场医学革命带给患者和医疗保健系统。 P4医学将对社会产生深远影响-转变医疗体系,扭转医疗成本不断攀升,数字化医学实践并为那些接受这场革命的组织和国家创造巨大的经济机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号